CENTRAL TRUST Co decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the fourth quarter, Holdings Channel reports. The firm owned 70,564 shares of the biopharmaceutical company’s stock after selling 852 shares during the quarter. CENTRAL TRUST Co’s holdings in Gilead Sciences were worth $5,055,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Webster Bank N. A. raised its position in Gilead Sciences by 108.7% during the 4th quarter. Webster Bank N. A. now owns 2,928 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 1,525 shares during the last quarter. James Investment Research Inc. raised its position in shares of Gilead Sciences by 23.2% in the 4th quarter. James Investment Research Inc. now owns 40,524 shares of the biopharmaceutical company’s stock worth $2,903,000 after acquiring an additional 7,644 shares in the last quarter. Regentatlantic Capital LLC raised its position in shares of Gilead Sciences by 5.7% in the 4th quarter. Regentatlantic Capital LLC now owns 58,072 shares of the biopharmaceutical company’s stock worth $4,160,000 after acquiring an additional 3,147 shares in the last quarter. Bredin Investment LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $842,000. Finally, Narwhal Capital Management raised its position in shares of Gilead Sciences by 7.6% in the 4th quarter. Narwhal Capital Management now owns 42,310 shares of the biopharmaceutical company’s stock worth $3,031,000 after acquiring an additional 2,980 shares in the last quarter. 75.71% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on GILD shares. Mizuho increased their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Maxim Group set a $94.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, December 11th. Credit Suisse Group reissued a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. Finally, Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $81.19 to $93.00 in a research report on Friday, January 26th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $86.92.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period last year, the business posted $2.70 EPS. The company’s revenue was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 27.08%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the sale, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the sale, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 432,768 shares of company stock worth $33,919,138. Company insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3222520/gilead-sciences-inc-gild-holdings-reduced-by-central-trust-co.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.